Take an in-depth look at our research on Silicasomes and the utility of the Silicasome platform.
The current two leading targets for silicasome-encapsulated cancer therapeutic molecules are:
As seen in the images, Irinotecan carried by Silicasomes™ (Ir-LB-MSNP) reduced tumor metastasis significantly compared to administering the drug by itself (Free IRIN), and compared to the drug delivered in liposomes (Ir-liposome) in an animal model.
Shown below are a few techniques in which we can use Silicasomes for encapsulated delivery therapy.
Meet the experts who are leading our research